Related Experiment Video
Updated: Sep 19, 2025
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Managing retinoblastoma in 2025
Eugenia M Ramos-Dávila1, Basil K Williams2, Maura Di Nicola2
1Tecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences., Monterrey, Mexico.
Purpose Of Review:
The management of retinoblastoma is an evolving field, with ongoing research focused on novel diagnostic techniques and therapeutic interventions. This review aims to summarize the current treatment options for retinoblastoma and explore future directions in the field.
Recent Findings:
Early diagnosis remains crucial for improving prognosis in retinoblastoma, as prompt identification significantly enhances treatment success. New diagnostic imaging strategies as well as prenatal testing are being developed to detect subclinical disease in high-risk patients, allowing for earlier intervention. Recurrent or refractory disease remains a challenge, but encouraging results have been observed with intravenous chemotherapy, intra-arterial chemotherapy, and intravitreal chemotherapy as salvage therapies. Other strategies, including anterior chamber chemotherapy, novel drug formulations, and advanced delivery methods like sustained release chemotherapy in the form of a chemoplaque, are being explored to address these persistent challenges.
Summary:
Significant progress in retinoblastoma treatment has led to a dramatic improvement in globe salvage rates. Nevertheless, challenges remain. Delayed diagnosis, particularly in low-income and middle-income regions, continues to contribute to reduced survival rates. Additionally, the management of advanced disease, as well as recurrent or refractory tumors, remain critical issues. The development of new drugs and delivery methods as well as modified treatment strategies offer promise in overcoming these obstacles.
Insights
Early diagnosis and novel therapies improve outcomes for retinoblastoma, a childhood eye cancer. Research focuses on advanced treatments for recurrent or refractory disease, enhancing survival rates globally.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Cancer Genetics
Background:
- Retinoblastoma management is evolving with new diagnostic and therapeutic research.
- Early detection significantly impacts prognosis and treatment success.
Purpose of the Study:
- To summarize current retinoblastoma treatment options.
- To explore future research directions in retinoblastoma management.
Main Methods:
- Review of current literature on retinoblastoma diagnosis and treatment.
- Analysis of novel therapeutic strategies and delivery methods.
Main Results:
- Early diagnosis using advanced imaging and prenatal testing improves outcomes.
- Salvage therapies including chemotherapy (intravenous, intra-arterial, intravitreal) show promise for recurrent/refractory disease.
- Novel drug formulations and delivery systems are under investigation.
Conclusions:
- Globe salvage rates have improved due to treatment advancements.
- Delayed diagnosis and managing advanced/refractory retinoblastoma remain challenges.
- New drugs, delivery methods, and treatment strategies offer hope for improved outcomes.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
02:56Treatment Resistant Cancers
01:25Glaucoma: Overview